- Home
- AUC vs MCRB Comparison
AUC vs MCRB Comparison
Compare AUC & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUC | MCRB |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | 6 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.1M | 71.0M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | AUC | MCRB |
|---|---|---|
| Price | $7.19 | $4.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 4.9K | ★ 89.7K |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.82 | $4.59 |
| 52 Week High | $8.58 | $29.98 |
Technical Indicators
Market Signals| Indicator | AUC | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 52.52 | 31.10 |
| Support Level | $7.06 | N/A |
| Resistance Level | $8.54 | $9.53 |
| Average True Range (ATR) | 0.52 | 0.38 |
| MACD | -0.15 | -0.05 |
| Stochastic Oscillator | 54.39 | 9.87 |
Price Performance
Historical ComparisonAbout AUC ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial consulting services to small and medium-sized enterprises. It operates in one operating segment, which is the consulting service business. The company prominently generated revenues from consulting services to its clients. Geographically, the maximum revenue is derived from Hong Kong.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.